We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+2.97%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.74B
AUM Growth
+$71.7M
Cap. Flow
+$132M
Cap. Flow %
7.63%
Top 10 Hldgs %
59.59%
Holding
81
New
17
Increased
17
Reduced
15
Closed
14

Top Buys

Rank Stock Value
1
JBIO
Jade Biosciences
JBIO
+$85.8M
2
VERA icon
Vera Therapeutics
VERA
+$45.3M
3
BIIB icon
Biogen
BIIB
+$33.5M
4
HRTX icon
Heron Therapeutics
HRTX
+$23.3M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$22.6M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$42.1M
2
LLY icon
Eli Lilly
LLY
+$33.7M
3
MRUS
Merus
MRUS
+$27.4M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$17.9M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTO
76
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-1,549
Closed -$4.16M
CCXI
77
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-150,000
Closed -$7.69M
CALA
78
DELISTED
Calithera Biosciences, Inc
CALA
– –
-37,877
Closed -$1.83M
ARNA
79
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-91,448
Closed -$6.35M
HZNP
80
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-133,997
Closed -$12.3M
1 2 3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2021 Portfolio in Review

As of Q2 2021, Sofinnova Investments held 81 positions worth $1.74B, up 4.3% from $1.66B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments deployed $132M of net new capital in Q2 2021, opening 17 new positions and adding to 17 existing holdings. Its largest new stake was Jade Biosciences: 107,391 shares worth $85.8M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $17.9M trimmed.

  • Sofinnova Investments's largest Q2 2021 buy was Jade Biosciences: 107,391 shares worth $85.8M.
  • Sofinnova Investments added most to Insulet in Q2 2021, an estimated $13.9M increase.
  • Sofinnova Investments's biggest Q2 2021 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $17.9M.
  • Sofinnova Investments fully exited Jazz Pharmaceuticals in Q2 2021, selling an estimated $42.1M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.74B portfolio in Q2 2021.
  • Sofinnova Investments opened 17 new positions and closed 14 in Q2 2021.
  • Sofinnova Investments's portfolio value rose 4.3% quarter-over-quarter to $1.74B.

Based on Sofinnova Investments's 13F filing for Q2 2021, filed 16 Aug 2021.